Vicki Osborne

InstitutionUniversity of Portsmouth
AddressPortsmouth
United Kingdom
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 1 publications in July 2020 and August 2020 and October 2020 and January 2021 and July 2021
    All Publications
    Bar chart showing 21 publications over 8 distinct years, with a maximum of 5 publications in 2017 and 2018
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Osborne V. Opioids in the United Kingdom: safety and surveillance during COVID-19. Curr Opin Psychiatry. 2021 07 01; 34(4):357-362. PMID: 33993168.
      Citations:    Fields:    Translation:HumansPHPublic Health
    2. Osborne V, Shakir SAW. What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19. Front Pharmacol. 2020; 11:569189. PMID: 33584254.
      Citations:    
    3. Dhanda S, Osborne V, Lynn E, Shakir S. Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? BMJ Evid Based Med. 2022 02; 27(1):1-6. PMID: 33087452.
      Citations: 8     Fields:    
    4. Osborne V, Davies M, Lane S, Evans A, Denyer J, Dhanda S, Roy D, Shakir S. Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Saf. 2020 08; 43(8):809-821. PMID: 32578156.
      Citations: 19     Fields:    Translation:HumansCellsPHPublic Health
    5. Davies M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, Shakir S. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Drug Saf. 2020 07; 43(7):645-656. PMID: 32468196.
      Citations: 24     Fields:    Translation:HumansCellsPHPublic Health
    6. Min J, Osborne V, Lynn E, Shakir SAW. First Conference on Big Data for Pharmacovigilance. Drug Saf. 2018 12; 41(12):1281-1284. PMID: 30232742.
      Citations:    Fields:    Translation:Humans
    7. Osborne V, Striley CW, Nixon SJ, Winterstein AG, Cottler LB. Sex differences in patterns of prescription opioid non-medical use among 10-18?year olds in the US. Addict Behav. 2019 02; 89:163-171. PMID: 30316142.
      Citations: 5     Fields:    Translation:Humans
    8. Min J, Osborne V, Kowalski A, Prosperi M. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System. Drug Saf. 2018 Mar; 41(3):313-320. PMID: 29098610.
      Citations: 7     Fields:    Translation:Humans
    9. Osborne V, Davies M, Layton D, Shakir SAW. Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England. Drug Saf. 2018 03; 41(3):267-275. PMID: 29019038.
      Citations: 4     Fields:    Translation:Humans
    10. Osborne V, Shakir SAW. The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance. Drug Saf. 2018 Jan; 41(1):139-141. PMID: 28795368.
      Citations:    Fields:    Translation:Humans
    11. Jones AA, Gerke T, Striley CW, Whitehead N, Osborne V, Cottler LB. One Step at a Time: A Latent Transitional Analysis on Changes in Substance Use, Exposure to Violence, and HIV/AIDS Risk Behaviors among Female Offenders. Am J Crim Justice. 2018 Sep; 43(3):471-485. PMID: 30220837.
      Citations: 1     
    12. Osborne V, Layton D, Fogg C, Tong E, Shakir SAW. Safety of Atrovent® CFC-free inhaler: respiratory events reported from an observational cohort study in England. Int J Pharm Pract. 2018 Aug; 26(4):356-363. PMID: 28990234.
      Citations:    Fields:    Translation:Humans
    13. Serdarevic M, Osborne V, Striley CW, Cottler LB. The association between insomnia and prescription opioid use: results from a community sample in Northeast Florida. Sleep Health. 2017 10; 3(5):368-372. PMID: 28923194.
      Citations: 5     Fields:    Translation:Humans
    14. Osborne V, Serdarevic M. Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. Addiction. 2017 08; 112(8):1509-1510. PMID: 28608368.
      Citations:    Fields:    Translation:Humans
    15. Osborne V, Serdarevic M, Crooke H, Striley C, Cottler LB. Non-medical opioid use in youth: Gender differences in risk factors and prevalence. Addict Behav. 2017 09; 72:114-119. PMID: 28391071.
      Citations: 18     Fields:    Translation:Humans
    16. Osborne V. Impact of survival bias on opioid-related outcomes when using death as an exclusion criterion. Pharmacoepidemiol Drug Saf. 2016 Apr; 25(4):476. PMID: 27059544.
      Citations:    Fields:    Translation:Humans
    17. Layton D, Osborne V, Al-Shukri M, Shakir SA. Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management. Drug Saf. 2014 Aug; 37(8):639-50. PMID: 24969120.
      Citations: 4     Fields:    Translation:Humans
    18. Osborne V, Layton D, Shakir SA. Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch). Post Reprod Health. 2014 Jun; 20(2):48-54. PMID: 24879745.
      Citations: 1     Fields:    
    19. Layton D, Osborne V, Gilchrist A, Shakir SA. Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data. Drug Saf. 2011 Dec 01; 34(12):1177-89. PMID: 22077506.
      Citations: 1     Fields:    Translation:Humans
    20. Osborne V, Layton D, Perrio M, Wilton L, Shakir SA. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England. Drug Saf. 2010 Jul 01; 33(7):579-91. PMID: 20553059.
      Citations: 9     Fields:    Translation:Humans
    21. Osborne V, Hazell L, Layton D, Shakir SA. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management. Drug Saf. 2010 Mar 01; 33(3):213-21. PMID: 20158285.
      Citations: 1     Fields:    Translation:Humans